Monday, 10 August 2020

Dassault Systemes partners in Drug Discovery Hackathon 2020

31 July 2020 | News

Aims to establish an open innovation model for in silico drug discovery against COVID-19

image credit- shutterstock.com

image credit- shutterstock.com

Bengaluru based Dassault Systemes has partnered in the Drug Discovery Hackathon 2020 (DDH2020), a joint initiative of AICTE (All India Council for Technical Education), CSIR (Council of Scientific and Industrial Research), CDAC (Centre for Development of Advanced Computing) and supported by the Office of Principal Scientific Advisor, Govt. of India, NIC (National Informatics Centre) and MyGov. Under the partnership, Dassault Systèmes is offering academic researchers, faculty and participants of the hackathon, access to BIOVIA Discovery Studio powered by 3DEXPERIENCE platform to assist in the search for rapid, safe and effective therapeutic drugs against COVID-19.

The Drug Discovery Hackathon 2020 (DDH2020) vision and mission is to establish an “open innovation model” for in silico drug discovery against COVID-19 and will cover the various processes in drug discovery including, but not limited to, in silico screening of molecules, lead optimization and identification of druggable non-toxic targets.

The targets, tools, or lead molecules identified through the process of DDH2020 will be taken forward for synthesis followed by subsequent steps in a routine drug discovery program.

As an active supporter of the scientific community worldwide that is collaborating on COVID-19 solutions, Dassault Systèmes has developed BIOVIA Discovery Studio.

It provides researchers with a complete toolset for use, from target identification through lead optimization including tools for biologics design and analysis, classical simulations, structure- and fragment-based design, virtual ligand screening, as well as ADME (Absorption, Distribution, Metabolism, Excretion) and toxicity prediction.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account